Genzyme to gain prenatal genetic testing risk assessment service via Genetrix buy.
This article was originally published in The Gray Sheet
Executive Summary
GENZYME GAINING PRENATAL GENETIC RISK ASSESSMENT PROGRAM VIA GENETRIX acquisition. On Feb. 14, Genzyme announced that it had signed agreement to acquire the privately held Phoenix-based genetic testing company in a stock swap valued at $36.7 mil. In addition to providing genetic testing for cancer monitoring, Genetrix offers a genetic risk assessment service designed to oversee the utilization of prenatal testing for managed care networks in exchange for a capitated fee. Genetrix set up the managed care program a year ago and expects to sign a contract with its first customer, a third-party administrator in Maryland, by the beginning of March.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.